Drug Screening Market

Drug Screening Market by Product (Consumables, Urine testing devices, Analytical, Breathalyzer, Chromatography) & Services, Sample Type (Urine, Breath), End User (Workplace, Laboratories, Criminal Justice, Hospitals) - Global Forecast to 2025

Report Code: MD 3239 Dec, 2020, by marketsandmarkets.com

[192 Pages Report] The global drug screening market is projected to reach USD 10.0 billion by 2025, from USD 4.5 billion in 2020, at a CAGR of 17.3%. Growth in this market is attributed to the rising drug & alcohol consumption, the enforcement of stringent laws mandating drug and alcohol testing, government funding in major markets, and regulatory approvals and product and service launches. On the other hand, bans on alcohol consumption in Islamic countries and the prohibition of drug testing at workplaces in certain regions are some major factors that may hinder the market growth

Drug Screening Market

To know about the assumptions considered for the study, Request for Free Sample Report

COVID-19 impact on the drug screening market

COVID-19 has resulted in significant disruptions to businesses and economic activities globally and is expected to have a short-term negative impact on the drug screening market due to limited or non-availability of medical facilities/treatment centers, harm reduction service providers, and the fear of infection transmission. To reduce the strain on the healthcare system and decrease disease transmission, various governments worldwide provided guidelines to postpone or delay non-essential medical and surgical procedures. Restrictions and lockdowns were also imposed in travel, business operations, public gatherings, and shelter-in-place orders, all of which have further impacted market growth. Several countries across the globe announcing nationwide lockdowns and the temporary closures of industries, manufacturing, production, and business development have been severely affected. Trade barriers have further negatively impacted the demand-supply gap. Companies operating in the drug screening market have witnessed disruptions in the global supply chain, reduced demand, or suspension of operations by their customers.

Global Drug screening Market Dynamics

DRIVER: Growing drug and alcohol consumption

Drug abuse and alcohol consumption are increasing across the globe. According to the World Drug Report 2019, in 2017, about 5.5% of the global population aged 15–64 consumed drugs at least once. In 2017, 35 million people had substance use disorders, a 14.8% increase from 30.5 million in 2016. In the same year, 585,000 people died as a result of drug use. The extent of harm caused by drugs is equal to losing 28 million years of “healthy” life (disability-adjusted life years or DALYs) globally. Alcohol consumption has shown similar increases, with consequences witnessed in the rising incidence of impaired driving. To curb the menace of drug and alcohol abuse, authorities in various countries are focusing on implementing comprehensive drug and alcohol testing measures. Thus, the demand for drug and alcohol testing is expected to increase in the coming years.

RESTRAINT: prohibition on workplace drug testing in some countries

Some countries, such as Canada, Colombia, Argentina, Chile, and South Africa, consider drug and alcohol testing at the workplace to be a violation of employee privacy. For instance, in France, pre-employment drug testing is only performed when physicians recommend the test. In Poland and the Czech Republic, drug and alcohol tests in the workplace are prohibited. In Canada, the Eastern Canadian case laws permit drug and alcohol testing only when workplace operations are inherently dangerous or where drug and alcohol testing is limited to a few special cases. This may hinder the adoption of drug and alcohol testing in these markets.

OPPORTUNITY: Emerging economies

Fingerprint-based drug testing is a relatively new concept that has gained ground due to the COVID-19 pandemic. The coronavirus has made it difficult to carry out drug testing in hospitals, labs, and other facilities because of the risk of transmitting the infection. Here, fingerprint-based drug screening can help limit the spread of COVID; it is non-invasive, less time-consuming, hygienic, enables social distancing, portable, user-friendly, and requires no specific preparation for sample collection and handling. This test is very easy to implement whenever and wherever required, thus offering flexible and effective workplace drug testing. The test analyzes small traces of sweat in the fingerprint to detect drug and drug metabolites. If this test is widely adopted, it is expected to replace urine, hair, and blood-based drug tests. This is a significant opportunity for the market players to capitalize on in the drug screening market.

The rapid testing devices segment will witness the highest growth during the forecast period.

Based on product, the drug screening market is segmented into analytical instruments, rapid testing devices, and consumables. Rapid testing devices market is further subsegmented into urine testing devices and oral fluid testing devices. The urine testing devices segment is expected to account for the largest market share in 2019. However, the oral fluid testing devices segment is projected to register highest CAGR during the forecast period. The high growth in this segment is attributed to the benefits it offers such as shorter detection window, non-invasive nature, and low risk of sample tampering.

The urine sample segment dominated the drug screening market in 2019.

The global drug screening market by sample type is segmented into urine, breath, oral fluid, hair, and other samples. The urine sample segment is estimated to account for the largest share in 2019; however, the oral fluid samples segment is expected to register the highest growth rate during the forecast period.

The workplace end-user segment accounted for the largest share of the drug screening market in 2019 and is also expected to grow at the highest CAGR during the forecast period.

Based on end-users, the drug screening market is segmented into workplaces, criminal justice systems & law enforcement, drug treatment centers, pain management centers, schools & colleges, hospitals, individual users, and drug testing laboratories. In 2019, the workplace testing segment is expected to account for the largest share of the market. The growth of this end-user segment can be attributed to the growing safety concerns in the workplace and the increasing number of organizations that have made regular drug screening mandatory.

Drug Screening Market  by Region

North America was the largest regional market for drug screening market in 2019.

The drug screening market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. In 2019, North America was the largest regional segment of the overall market, followed by Europe. The dominance of the North American market is attributed to factors such as rising consumption of illicit drugs, availability of government funding to curb drug abuse, and the presence of laws supporting drug screening, and growing burden of accidents due to unsafe levels of alcohol consumption.

Key Market Players

The prominent players operating in this market include LabCorp (US), Quest Diagnostics (US), Alere (US), OraSure (US), Alfa Scientific Designs (US), Thermo Fisher Scientific (US), Drδgerwerk (Germany), LifeLoc (US), MPD Inc. (US), Omega Laboratories (US), Premier Biotech (US), Psychemedics (US), Roche (Switzerland), Shimadzu (Japan), and Siemens Healthineers (Germany).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2018–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD)

Segments covered

Product and service, sample type, end user, and region

Geographies covered

North America, Europe, Asia Pacific, and the Rest of the World

Companies covered

LabCorp (US), Quest Diagnostics (US), Alere (US), OraSure (US), Alfa Scientific Designs (US), Thermo Fisher Scientific (US), Drδgerwerk (Germany), LifeLoc (US), MPD Inc. (US), Omega Laboratories (US), Premier Biotech (US), Psychemedics (US), Roche (Switzerland), Shimadzu (Japan), Siemens Healthineers (Germany), American Bio Medica Corporation (US), Sciteck, Inc. (US), ACM Global Laboratories (US), CareHealth America (US), and Clinical Reference Laboratory (US)

This report categorizes the drug screening market into the following segments and subsegments:

By Product and Service

  • Drug Screening Products
    • Analytical Instruments
      • Immunoassay Analyzers
      • Chromatography Instruments
      • Breathalyzers
        • Fuel-cell Breathalyzers
        • Semiconductor  Breathalyzers
        • Other Breathalyzers
    • Rapid Testing Devices
      • Urine Testing Devices
        • Drug Testing Cups
        • Dip Cards
        • Drug Testing Cassettes
      • Oral Fluid Testing Devices
    • Consumables
    • Assay Kits
    • Sample Collection Tubes
    • Calibrators & Controls
    • Other Consumables
  • Drug Screening Services

By Sample Type

  • Urine Samples
  • Oral Fluid Samples
  • Breath Samples
  • Hair Samples
  • Other Samples

By End User

  • Workplaces
  • Drug Testing Laboratories
  • Criminal Justice Systems & Law Enforcement Agencies
  • Hospitals
  • Drug Treatment Centers
  • Individual Users
  • Pain Management Centers
  • Schools & Colleges

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • RoE
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of Asia Pacific
  • Rest of the World
    • LATAM
    • MEA

Recent Developments

  • In 2020, LabCorp Entered into a multi-year agreement with Infirmary Health (US) to offer laboratory testg services in the eastern Gulf Coast.
  • In 2020, Psychemedics introduced a vaping panel test that detects the ingestion of marijuana, CBD, and nicotine drugs by all methods, including electronic cigarettes or smoking
  • In 2019, Quest Diagnostics acquired some assets of the clinical laboratory services business of Boston Clinical Laboratories. This allowed BCL’s patients and providers to access Quest services.
  • In 2017, Alfa Scientific Designs introduced a new product line, Instant-view-PLUS.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 28)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 MARKET STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 32)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
    2.2 SECONDARY DATA
           2.2.1 KEY DATA FROM SECONDARY SOURCES
    2.3 PRIMARY DATA
           2.3.1 PRIMARY SOURCES
           2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS
           FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION
           FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER AND REGION
    2.4 MARKET ESTIMATION
           2.4.1 BOTTOM-UP APPROACH
           2.4.2 TOP-DOWN APPROACH: CONTRIBUTION-BASED MARKET SIZE ESTIMATION
           FIGURE 4 DRUG SCREENING MARKET: TOP-DOWN APPROACH
           2.4.3 GROWTH FORECAST
    2.5 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 5 DATA TRIANGULATION METHODOLOGY
    2.6 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 42)
           FIGURE 6 DRUG SCREENING SERVICES MARKET TO RECORD HIGHEST CAGR DURING 2020–2025
           FIGURE 7 ANALYTICAL INSTRUMENTS SEGMENT TO LEAD THE DRUG SCREENING PRODUCTS MARKET, 2020–2025 (USD BILLION)
           FIGURE 8 WORKPLACES TO SHOW THE HIGHEST GROWTH IN THE END-USER MARKET, 2020–2025 (USD BILLION)
           FIGURE 9 GEOGRAPHIC SNAPSHOT OF THE DRUG SCREENING MARKET

4 PREMIUM INSIGHTS (Page No. - 46)
    4.1 ATTRACTIVE OPPORTUNITIES IN THE DRUG SCREENING MARKET
           FIGURE 10 GROWING CONSUMPTION OF DRUGS AND ALCOHOL TO DRIVE MARKET GROWTH
    4.2 DRUG SCREENING MARKET, BY PRODUCT & SERVICE
           FIGURE 11 SERVICES SEGMENT TO REGISTER HIGHEST CAGR DURING 2020–2025 (USD BILLION)
    4.3 DRUG SCREENING MARKET, BY SAMPLE TYPE
           FIGURE 12 ORAL FLUID SAMPLES SEGMENT TO WITNESS HIGHEST CAGR, 2020–2025 (USD BILLION)
    4.4 DRUG SCREENING MARKET: GEOGRAPHIC SNAPSHOT
           FIGURE 13 INDIA TO WITNESS HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 49)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 14 DRUG SCREENING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    5.3 MARKET DYNAMICS
           5.3.1 DRIVERS
                    5.3.1.1 Growing drug and alcohol consumption
                    5.3.1.2 Enforcement of stringent laws mandating drug and alcohol testing
                    5.3.1.3 Regulatory approvals and product & service launches
           TABLE 1 KEY PRODUCT & SERVICE LAUNCHES (2014–2017)
           TABLE 2 RECENT APPROVALS FOR DRUG AND ALCOHOL TESTING PRODUCTS AND SERVICES
           5.3.2 RESTRAINTS
                    5.3.2.1 Ban on alcohol consumption in several Islamic countries
                    5.3.2.2 Prohibition on workplace drug testing in some countries
           5.3.3 OPPORTUNITIES
                    5.3.3.1 Oral fluid testing
                    5.3.3.2 Fingerprint-based drug screening
                    5.3.3.3 Emerging economies
           5.3.4 CHALLENGES
                    5.3.4.1 Accuracy and specificity concerns related to breathalyzers
    5.4 VALUE CHAIN ANALYSIS
           FIGURE 15 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
    5.5 ECOSYSTEM ANALYSIS OF THE DRUG SCREENING PRODUCTS MARKET
           FIGURE 16 ECOSYSTEM ANALYSIS
    5.6 COVID-19 IMPACT ON THE DRUG SCREENING MARKET

6 DRUG SCREENING MARKET, BY PRODUCT & SERVICE (Page No. - 56)
    6.1 INTRODUCTION
           TABLE 3 DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
    6.2 DRUG SCREENING SERVICES
           6.2.1 GROWING DRUG CONSUMPTION AND STRINGENT LAWS HAVE ENSURED DEMAND SPIKE FOR SERVICES
           TABLE 4 DRUG SCREENING SERVICES MARKET, BY REGION, 2018–2025 (USD MILLION)
    6.3 DRUG SCREENING PRODUCTS
           TABLE 5 DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           6.3.1 ANALYTICAL INSTRUMENTS
           TABLE 6 DRUG SCREENING PRODUCTS MARKET FOR ANALYTICAL INSTRUMENTS,BY TYPE, 2018–2025 (USD MILLION)
           TABLE 7 DRUG SCREENING PRODUCTS MARKET FOR ANALYTICAL INSTRUMENTS, BY REGION, 2018–2025 (USD MILLION)
                    6.3.1.1 Breathalyzers
                               6.3.1.1.1 Law enforcement agencies widely use breathalyzers
           TABLE 8 BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 9 BREATHALYZERS MARKET, BY REGION, 2018–2025 (USD MILLION)
                               6.3.1.1.2 Fuel-cell breathalyzers
           TABLE 10 FUEL-CELL BREATHALYZERS MARKET, BY REGION,2018–2025 (USD MILLION)
                               6.3.1.1.3 Semiconductor breathalyzers
           TABLE 11 SEMICONDUCTOR BREATHALYZERS MARKET, BY REGION, 2018–2025 (USD MILLION)
                               6.3.1.1.4 Other breathalyzers
           TABLE 12 OTHER BREATHALYZERS MARKET, BY REGION, 2018–2025 (USD MILLION)
                    6.3.1.2 Immunoassay analyzers
                               6.3.1.2.1 North America is the largest market for immunoassay analyzers
           TABLE 13 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2018–2025 (USD MILLION)
                    6.3.1.3 Chromatography instruments
                               6.3.1.3.1 Chromatography shows higher accuracy than immunoassays
           TABLE 14 CHROMATOGRAPHY INSTRUMENTS MARKET, BY REGION, 2018–2025 (USD MILLION)
           6.3.2 RAPID TESTING DEVICES
           TABLE 15 DRUG SCREENING PRODUCTS MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 16 DRUG SCREENING PRODUCTS MARKET FOR RAPID TESTING DEVICES, BY REGION, 2018–2025 (USD MILLION)
                    6.3.2.1 Urine testing devices
                               6.3.2.1.1 Urine testing provides results within minutes and is used in a wide range of applications
           TABLE 17 URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 18 URINE TESTING DEVICES MARKET, BY REGION, 2018–2025 (USD MILLION)
                               6.3.2.1.2 Drug testing cups
           TABLE 19 DRUG TESTING CUPS MARKET, BY REGION, 2018–2025 (USD MILLION)
                               6.3.2.1.3 Dip cards
           TABLE 20 DIP CARDS MARKET, BY REGION, 2018–2025 (USD MILLION)
                               6.3.2.1.4 Drug testing cassettes
           TABLE 21 DRUG TESTING CASSETTES MARKET, BY REGION, 2018–2025 (USD MILLION)
                    6.3.2.2 Oral fluid testing devices
                               6.3.2.2.1 Short detection windows, noninvasive nature, and low chance of sample tampering have ensured interest in oral fluid testing
           TABLE 22 ORAL FLUID TESTING DEVICES MARKET, BY REGION, 2018–2025 (USD MILLION)
           6.3.3 CONSUMABLES
           TABLE 23 DRUG SCREENING CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 24 DRUG SCREENING CONSUMABLES MARKET, BY REGION, 2018–2025 (USD MILLION)
                    6.3.3.1 Assay kits
                               6.3.3.1.1 Immunoassay kits provide a rapid, inexpensive method to screen samples
           TABLE 25 ASSAY KITS MARKET, BY REGION, 2018–2025 (USD MILLION)
                    6.3.3.2 Sample collection devices
                               6.3.3.2.1 APAC market for sample collection devices to see high growth
           TABLE 26 SAMPLE COLLECTION DEVICES MARKET, BY REGION, 2018–2025 (USD MILLION)
                    6.3.3.3 Calibrators & controls
                               6.3.3.3.1 Thermo Fisher Scientific is a prominent manufacturer of calibrators & controls
           TABLE 27 CALIBRATORS & CONTROLS MARKET, BY REGION, 2018–2025 (USD MILLION)
                    6.3.3.4 Other consumables
           TABLE 28 OTHER CONSUMABLES MARKET, BY REGION, 2018–2025 (USD MILLION)

7 DRUG SCREENING MARKET, BY SAMPLE TYPE (Page No. - 71)
    7.1 INTRODUCTION
           TABLE 29 DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
    7.2 URINE SAMPLES
           7.2.1 EASE OF COLLECTION AND WELL-DEVELOPED TECHNOLOGY HAVE SUPPORTED THE USE OF URINE SAMPLES
           TABLE 30 DRUG SCREENING MARKET FOR URINE SAMPLES, BY REGION, 2018–2025 (USD MILLION)
    7.3 BREATH SAMPLES
           7.3.1 BREATH ALCOHOL TESTS SEE WIDE USAGE IN WORKPLACE TESTING AND LAW ENFORCEMENT APPLICATIONS
           TABLE 31 DRUG SCREENING MARKET FOR BREATH SAMPLES, BY REGION, 2018–2025 (USD MILLION)
    7.4 ORAL FLUID SAMPLES
           7.4.1 NONINVASIVE SAMPLE COLLECTION AND LOW CHANCE OF ADULTERATION HAVE SUPPORTED RELIANCE ON ORAL SAMPLES
           TABLE 32 DRUG SCREENING MARKET FOR ORAL FLUID SAMPLES, BY REGION, 2018–2025 (USD MILLION)
    7.5 HAIR SAMPLES
           7.5.1 HAIR SAMPLES CAN PROVIDE INSIGHTS INTO LONG-TERM DRUG USE
           TABLE 33 DRUG SCREENING MARKET FOR HAIR SAMPLES, BY REGION, 2018–2025 (USD MILLION)
    7.6 OTHER SAMPLES
           TABLE 34 DRUG SCREENING MARKET FOR OTHER SAMPLES, BY REGION, 2018–2025 (USD MILLION)

8 DRUG SCREENING MARKET, BY END USER (Page No. - 77)
    8.1 INTRODUCTION
           TABLE 35 DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
    8.2 WORKPLACES
           8.2.1 WORKPLACES TO SHOW THE HIGHEST GROWTH OF ALL END-USER SEGMENTS
           TABLE 36 DRUG SCREENING MARKET FOR WORKPLACES, BY REGION, 2018–2025 (USD MILLION)
    8.3 DRUG TESTING LABORATORIES
           8.3.1 RISING NUMBER OF DRUG ABUSE CASES AND DEVELOPMENT OF SPECIALIZED ASSAYS AND TESTS SUPPORT MARKET GROWTH
           TABLE 37 DRUG SCREENING MARKET FOR DRUG TESTING LABORATORIES, BY REGION, 2018–2025 (USD MILLION)
    8.4 CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES
           8.4.1 URINE IS THE MOST COMMONLY USED SAMPLE IN CRIMINAL JUSTICE SYSTEMS
           TABLE 38 DRUG SCREENING MARKET FOR CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES, BY REGION, 2018–2025 (USD MILLION)
    8.5 HOSPITALS
           8.5.1 RISING DRUG ABUSE INCIDENCE HAS RESULTED IN AN INCREASE IN EMERGENCY DEPARTMENT VISITS
           TABLE 39 DRUG SCREENING MARKET FOR HOSPITALS, BY REGION, 2018–2025 (USD MILLION)
    8.6 DRUG TREATMENT CENTERS
           8.6.1 AVAILABILITY OF GOVERNMENT SUPPORT IS A KEY GROWTH DRIVER
           TABLE 40 DRUG SCREENING MARKET FOR DRUG TREATMENT CENTERS, BY REGION, 2018–2025 (USD MILLION)
    8.7 INDIVIDUAL USERS
           8.7.1 PERSONAL BREATHALYZERS HAVE SEEN GROWING ADOPTION
           TABLE 41 DRUG SCREENING MARKET FOR INDIVIDUAL USERS, BY REGION, 2018–2025 (USD MILLION)
    8.8 PAIN MANAGEMENT CENTERS
           8.8.1 RISING SUBSTANCE ABUSE HAS SUPPORTED DRUG TESTING ACTIVITY IN PAIN MANAGEMENT APPLICATIONS
           TABLE 42 DRUG SCREENING MARKET FOR PAIN MANAGEMENT CENTERS, BY REGION, 2018–2025 (USD MILLION)
    8.9 SCHOOLS & COLLEGES
           8.9.1 WHILE SOME COUNTRIES SUPPORT DRUG TESTS IN SCHOOLS & COLLEGES, OTHERS ARE OPPOSED OR HAVE BANNED TESTING
           TABLE 43 DRUG SCREENING MARKET FOR SCHOOLS & COLLEGES, BY REGION, 2018–2025 (USD MILLION)

9 DRUG SCREENING MARKET, BY REGION (Page No. - 85)
    9.1 INTRODUCTION
           TABLE 44 DRUG SCREENING MARKET, BY REGION, 2018–2025 (USD MILLION)
    9.2 NORTH AMERICA
           FIGURE 17 NORTH AMERICA: DRUG SCREENING MARKET SNAPSHOT
           TABLE 45 NORTH AMERICA: DRUG SCREENING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 46 NORTH AMERICA: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 47 NORTH AMERICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 48 NORTH AMERICA: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 49 NORTH AMERICA: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 50 NORTH AMERICA: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 51 NORTH AMERICA: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 52 NORTH AMERICA: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 53 NORTH AMERICA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 54 NORTH AMERICA: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.2.1 US
                    9.2.1.1 The US holds the largest share of the market in North America
           TABLE 55 US: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 56 US: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 57 US: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 58 US: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 59 US: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 60 US: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 61 US: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 62 US: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 63 US: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Canada has no legislation governing drug and alcohol testing in the workplace
           TABLE 64 CANADA: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 65 CANADA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 66 CANADA: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 67 CANADA: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 68 CANADA: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 69 CANADA: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 70 CANADA: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 71 CANADA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 72 CANADA: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
    9.3 EUROPE
           TABLE 73 EUROPE: DRUG SCREENING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 74 EUROPE: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 75 EUROPE: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 76 EUROPE: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 77 EUROPE: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 78 EUROPE: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 79 EUROPE: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 80 EUROPE: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 81 EUROPE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 82 EUROPE: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Germany is the largest market for drug screening products & services in Europe
           TABLE 83 GERMANY: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 84 GERMANY: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 85 GERMANY: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 86 GERMANY: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 87 GERMANY: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 88 GERMANY: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 89 GERMANY: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 90 GERMANY: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 91 GERMANY: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.2 FRANCE
                    9.3.2.1 Cannabis and cocaine are the most widely used illicit substances in France
           TABLE 92 FRANCE: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 93 FRANCE: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 94 FRANCE: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 95 FRANCE: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 96 FRANCE: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 97 FRANCE: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 98 FRANCE: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 99 FRANCE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 100 FRANCE: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.3 UK
                    9.3.3.1 Favorable government support is a prominent driver of market growth in the UK
           TABLE 101 UK: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 102 UK: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 103 UK: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 104 UK: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 105 UK: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 106 UK: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 107 UK: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 108 UK: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 109 UK: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.3.4 ROE
           TABLE 110 ROE: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 111 ROE: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 112 ROE: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,2018–2025 (USD MILLION)
           TABLE 113 ROE: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 114 ROE: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 115 ROE: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 116 ROE: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 117 ROE: DRUG SCREENING MARKET, BY SAMPLE TYPE,2018–2025 (USD MILLION)
           TABLE 118 ROE: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
    9.4 APAC
           FIGURE 18 APAC: DRUG SCREENING MARKET SNAPSHOT
           TABLE 119 APAC: DRUG SCREENING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 120 APAC: DRUG SCREENING MARKET, BY PRODUCT & SERVICE,2018–2025 (USD MILLION)
           TABLE 121 APAC: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 122 APAC: ANALYTICAL INSTRUMENTS MARKET, BY TYPE,2018–2025 (USD MILLION)
           TABLE 123 APAC: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 124 APAC: RAPID TESTING DEVICES MARKET, BY TYPE,2018–2025 (USD MILLION)
           TABLE 125 APAC: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 126 APAC: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 127 APAC: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 128 APAC: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 China holds the largest share of the APAC market
           TABLE 129 CHINA: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 130 CHINA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 131 CHINA: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 132 CHINA: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 133 CHINA: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 134 CHINA: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 135 CHINA: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 136 CHINA: DRUG SCREENING MARKET, BY SAMPLE TYPE,2018–2025 (USD MILLION)
           TABLE 137 CHINA: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Stringent laws and growing awareness are key market drivers in Japan
           TABLE 138 JAPAN: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 139 JAPAN: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 140 JAPAN: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 141 JAPAN: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 142 JAPAN: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 143 JAPAN: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 144 JAPAN: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 145 JAPAN: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 146 JAPAN: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 India is among the fastest-growing segments of the drug screening market
           TABLE 147 INDIA: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 148 INDIA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 149 INDIA: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 150 INDIA: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 151 INDIA: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 152 INDIA: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 153 INDIA: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 154 INDIA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 155 INDIA: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.4.4 ROAPAC
           TABLE 156 ROAPAC: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 157 ROAPAC: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 158 ROAPAC: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 159 ROAPAC: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 160 ROAPAC: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 161 ROAPAC: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 162 ROAPAC: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 163 ROAPAC: DRUG SCREENING MARKET, BY SAMPLE TYPE,2018–2025 (USD MILLION)
           TABLE 164 ROAPAC: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
    9.5 ROW
           TABLE 165 ROW: DRUG SCREENING MARKET, BY REGION, 2018–2025 (USD MILLION)
           TABLE 166 ROW: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 167 ROW: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 168 ROW: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 169 ROW: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 170 ROW: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 171 ROW: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 172 ROW: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 173 ROW: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 174 ROW: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.5.1 LATAM
                    9.5.1.1 Increasing incidence of drug overdose and favorable government support are key growth drivers in LATAM
           TABLE 175 LATAM: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 176 LATAM: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 177 LATAM: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 178 LATAM: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 179 LATAM: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 180 LATAM: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 181 LATAM: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 182 LATAM: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 183 LATAM: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)
           9.5.2 MIDDLE EAST & AFRICA
                    9.5.2.1 Rising drug abuse and growing emphasis on testing support market growth in the MEA
           TABLE 184 MEA: DRUG SCREENING MARKET, BY PRODUCT & SERVICE, 2018–2025 (USD MILLION)
           TABLE 185 MEA: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 186 MEA: ANALYTICAL INSTRUMENTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 187 MEA: BREATHALYZERS MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 188 MEA: RAPID TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 189 MEA: URINE TESTING DEVICES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 190 MEA: CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 191 MEA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2018–2025 (USD MILLION)
           TABLE 192 MEA: DRUG SCREENING MARKET, BY END USER, 2018–2025 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 139)
     10.1 OVERVIEW
           FIGURE 19 KEY PLAYERS ADOPTED ORGANIC AS WELL AS INORGANIC GROWTH STRATEGIES BETWEEN 2017 AND 2020
           FIGURE 20 MARKET EVOLUTION FRAMEWORK
     10.2 COMPETITIVE SITUATIONS AND TRENDS
             10.2.1 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2017–2020)
             10.2.2 PRODUCT LAUNCHES (2017–2020)
             10.2.3 APPROVALS (2017–2020)
             10.2.4 EXPANSIONS (2017–2020)
             10.2.5 ACQUISITIONS (2017-2020)

11 COMPANY EVALUATION MATRIX AND COMPANY PROFILES (Page No. - 144)
     11.1 COMPANY EVALUATION MATRIX DEFINITIONS AND METHODOLOGY
             11.1.1 MARKET PLAYER RANKING, 2019
           FIGURE 21 DRUG SCREENING SERVICES MARKET RANKING, BY KEY PLAYER, 2019
           FIGURE 22 RAPID TESTING DEVICES MARKET RANKING, BY KEY PLAYER, 2019
     11.2 COMPANY EVALUATION MATRIX
             11.2.1 STARS
             11.2.2 EMERGING LEADERS
             11.2.3 PERVASIVE PLAYERS
             11.2.4 PARTICIPANTS
           FIGURE 23 MNM VENDOR DIVE COMPARISON MATRIX: DRUG SCREENING MARKET
     11.3 COMPETITIVE LEADERSHIP MAPPING (START-UPS)
             11.3.1 PROGRESSIVE COMPANIES
             11.3.2 STARTING BLOCKS
             11.3.3 RESPONSIVE COMPANIES
             11.3.4 DYNAMIC COMPANIES
           FIGURE 24 MNM VENDOR DIVE COMPARISON MATRIX FOR START-UPS: DRUG SCREENING MARKET
     11.4 COMPANY PROFILES
     (Business Overview, Products Offered, Recent Developments, MnM View)* 
             11.4.1 LABCORP
           FIGURE 25 LABCORP: COMPANY SNAPSHOT (2019)
             11.4.2 QUEST DIAGNOSTICS
           FIGURE 26 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2019)
             11.4.3 ALERE
           FIGURE 27 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019)
             11.4.4 ORASURE
           FIGURE 28 ORASURE: COMPANY SNAPSHOTS (2019)
             11.4.5 ALFA SCIENTIFIC DESIGNS
             11.4.6 THERMO FISHER SCIENTIFIC
           FIGURE 29 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
             11.4.7 DRΔGERWERK
           FIGURE 30 DRΔGERWERK: COMPANY SNAPSHOT (2019)
             11.4.8 LIFELOC
           FIGURE 31 LIFELOC: COMPANY SNAPSHOT (2019)
             11.4.9 MPD INC.
             11.4.10 OMEGA LABORATORIES
             11.4.11 PREMIER BIOTECH
             11.4.12 PSYCHEMEDICS
           FIGURE 32 PSYCHEMEDICS: COMPANY SNAPSHOT (2019)
             11.4.13 ROCHE
           FIGURE 33 ROCHE: COMPANY SNAPSHOT (2019)
             11.4.14 SHIMADZU
           FIGURE 34 SHIMADZU: COMPANY SNAPSHOT (2019)
             11.4.15 SIEMENS HEALTHINEERS
           FIGURE 35 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2019)
             11.4.16 AMERICAN BIO MEDICA CORPORATION
             11.4.17 SCITECK, INC.
             11.4.18 ACM GLOBAL LABORATORIES
             11.4.19 CAREHEALTH AMERICA
             11.4.20 CLINICAL REFERENCE LABORATORY
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies. 

12 APPENDIX (Page No. - 185)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 AVAILABLE CUSTOMIZATIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

This study involved four major activities in estimating the current size of the drug screening market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the drug screening market. The secondary sources used for this study include World Health Organization (WHO), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism (NIAAA), Substance Abuse and Mental Health Services Administration (SAMHSA), European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Asia-Pacific Society for Alcohol and Addiction Research (APSAAR), National Institute on Drug Abuse (NIDA), Federation of Indian NGOs for Drugs and AIDS Prevention (FINGODAP), International Journal of Drug Policy, American Journal of Drug and Alcohol Abuse, Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Drug Screening Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the drug screening market as well as to estimate the market size of various other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the drug screening business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, and forecast the global drug screening market based on the product and service, sample type, end user and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
  • To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall drug screening market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product and services launches, approvals, expansions, agreements, partnerships, and R&D activities in the drug screening market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • An additional five company profiles
COVID-19

Get in-depth analysis of the COVID-19 impact on the Drug Screening Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Drug Screening Market

Request For Special Pricing
Report Code
MD 3239
Published ON
Dec, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Drug Screening Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved